Transgene Biotek [TRABI] vs OneSource Specialty [ONESOURCE] Detailed Stock Comparison

Transgene Biotek

BSE
Loading...

OneSource Specialty

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Transgene Biotek wins in 6 metrics, OneSource Specialty wins in 10 metrics, with 0 ties. OneSource Specialty appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricTransgene BiotekOneSource SpecialtyBetter
P/E Ratio (TTM)-48.67-1,139.69OneSource Specialty
Price-to-Book Ratio3.043.59Transgene Biotek
Debt-to-Equity Ratio144.7716.03OneSource Specialty
PEG Ratio0.16N/AN/A
EV/EBITDA-47.4433.32Transgene Biotek
Profit Margin (TTM)100.00%-0.85%Transgene Biotek
Operating Margin (TTM)-380.20%6.32%OneSource Specialty
EBITDA Margin (TTM)N/A6.32%N/A
Return on Equity-6.74%-0.31%OneSource Specialty
Return on Assets (TTM)-0.47%-0.24%OneSource Specialty
Free Cash Flow (TTM)$-5.04M$-1.96BTransgene Biotek
1-Year Return-43.99%7.34%OneSource Specialty
Price-to-Sales Ratio (TTM)116.7014.29OneSource Specialty
Enterprise Value$415.59M$180.12BOneSource Specialty
EV/Revenue Ratio159.2312.17OneSource Specialty
Gross Profit Margin (TTM)100.00%71.61%Transgene Biotek
Revenue per Share (TTM)$0$139OneSource Specialty
Earnings per Share (Diluted)$-0.18$-1.12Transgene Biotek
Beta (Stock Volatility)0.80N/AN/A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Transgene Biotek vs OneSource Specialty Stock Performance Analysis

Loading Price Chart...

Transgene Biotek
OneSource Specialty
Transgene Biotek Stock Overview | OneSource Specialty Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Transgene Biotek-9.82%14.66%-1.13%1.86%14.06%-28.78%
OneSource Specialty1.33%-0.35%0.29%-15.42%25.01%7.34%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Transgene Biotek-43.99%36.45%-0.45%48.98%-91.63%-95.45%
OneSource Specialty7.34%7.34%7.34%7.34%7.34%7.34%

News Based Sentiment: Transgene Biotek vs OneSource Specialty

Transgene Biotek

News based Sentiment: NEGATIVE

The initiation of insolvency proceedings is a game-changing event for Transgene Biotek Ltd., significantly increasing the risk for investors. Coupled with consistent losses and a declining market cap, the company faces a very uncertain future, making this a critical month for its investment story.

View Transgene Biotek News Sentiment Analysis

OneSource Specialty

News based Sentiment: MIXED

OneSource Specialty Pharma experienced a strong FY25 but faced a significant profitability decline in Q1 FY26. While analysts remain optimistic with a 'BUY' rating, mixed investor activity and declining search interest suggest caution. The upcoming AGM will be crucial for addressing investor concerns and outlining the path to improved profitability.

View OneSource Specialty News Sentiment Analysis

Performance & Financial Health Analysis: Transgene Biotek vs OneSource Specialty

MetricTRABIONESOURCE
Market Information
Market Cap i₹335.38M₹211.08B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i95,533111,122
90 Day Avg. Volume i53,167146,302
Last Close₹3.95₹1,859.90
52 Week Range₹3.22 - ₹7.71₹1,209.95 - ₹2,248.00
% from 52W High-48.77%-17.26%
All-Time High₹322.50 (Jan 23, 2006)₹2,248.00 (Jun 18, 2025)
% from All-Time High-98.78%-17.26%
Growth Metrics
Quarterly Revenue Growth0.00%3.18%
Quarterly Earnings Growth0.01%N/A
Financial Health
Profit Margin (TTM) i1.00%-0.01%
Operating Margin (TTM) i-3.80%0.06%
Return on Equity (TTM) i-0.07%0.00%
Debt to Equity (MRQ) i144.7716.03
Cash & Liquidity
Book Value per Share (MRQ)₹1.32₹514.02
Cash per Share (MRQ)₹0.04₹33.31
Operating Cash Flow (TTM) i₹1.93M₹-2,152,760,000
Levered Free Cash Flow (TTM) i₹-6,761,000₹-179,710,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Transgene Biotek vs OneSource Specialty

MetricTRABIONESOURCE
Price Ratios
P/E Ratio (TTM) i-48.67-1,139.69
Forward P/E iN/A27.12
PEG Ratio i0.16N/A
Price to Sales (TTM) i116.7014.29
Price to Book (MRQ) i3.043.59
Market Capitalization
Market Capitalization i₹335.38M₹211.08B
Enterprise Value i₹415.59M₹180.12B
Enterprise Value Metrics
Enterprise to Revenue i159.2312.17
Enterprise to EBITDA i-47.4433.32
Risk & Other Metrics
Beta i0.80N/A
Book Value per Share (MRQ) i₹1.32₹514.02

Financial Statements Comparison: Transgene Biotek vs OneSource Specialty

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TRABIONESOURCE
Revenue/Sales i₹765,000₹3.27B
Cost of Goods Sold i₹0₹929.19M
Gross Profit i₹765,000₹2.34B
Research & Development iN/AN/A
Operating Income (EBIT) i₹-5.66M₹206.81M
EBITDA i₹-4.98M₹937.52M
Pre-Tax Income i₹-7.13M₹-43.99M
Income Tax i₹0₹-42.13M
Net Income (Profit) i₹-7.13M₹-1.86M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TRABIONESOURCE
Cash & Equivalents i₹2.84MN/A
Total Current Assets i₹12.64MN/A
Total Current Liabilities i₹127.38MN/A
Long-Term Debt i₹61.03MN/A
Total Shareholders Equity i₹100.30MN/A
Retained Earnings iN/AN/A
Property, Plant & Equipment i₹32.85MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TRABIONESOURCE
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTRABIONESOURCE
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i95,533111,122
Average Daily Volume (90 Day) i53,167146,302
Shares Outstanding i75.77M114.44M
Float Shares i48.28M55.57M
% Held by Insiders i0.22%0.41%
% Held by Institutions i0.00%0.26%

Dividend Analysis & Yield Comparison: Transgene Biotek vs OneSource Specialty

MetricTRABIONESOURCE
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A